Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1

被引：1

作者：

Locke, Frederick L. ^{[1
]}

Ghobadi, Armin ^{[2
]}

Lekakis, Lazaros J. ^{[3
]}

Miklos, David B. ^{[4
]}

Jacobson, Caron A. ^{[5
]}

Jacobsen, Eric ^{[5
]}

Braunschweig, Ira ^{[6
]}

Oluwole, Olalekan O. ^{[7
]}

Siddiqi, Tanya ^{[8
]}

Lin, Yi ^{[9
]}

Reagan, Patrick M. ^{[10
]}

Farooq, Umar ^{[11
]}

Deol, Abhinav ^{[12
]}

Bot, Adrian ^{[13
]}

Rossi, John M. ^{[13
]}

Jiang, Yizhou ^{[13
]}

Xue, Allen ^{[13
]}

Go, William Y. ^{[13
]}

Neelapu, Sattva S. ^{[14
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Washington Univ, Sch Med, St Louis, MO USA

[3] Univ Miami Hlth Syst, Sylvester Comprehens Care Ctr, Miami, FL USA

[4] Stanford Univ, Stanford, CA 94305 USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA

[7] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[9] Mayo Clin, Rochester, MN USA

[10] Univ Rochester, Sch Med, Rochester, NY USA

[11] Univ Iowa, Iowa City, IA USA

[12] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA

[13] Kite, Santa Monica, CA USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷

关键词：

CAR T cell therapy; large B cell lymphoma;

D O I：

10.1016/j.clml.2018.07.203

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

NHL-102

引用

页码：S276 / S276

页数：1

共 50 条

[1] Outcomes by Prior Lines of Therapy in ZUMA-1, the Pivotal Phase 2 Study of Axicabtagene Ciloleucel in Patients With Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 11 - 13
[2] Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
Neelapu, Sattva S.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Deol, Abhinav
Miklos, David B.
Bartlett, Nancy L.
Braunschweig, Ira
Jiang, Yizhou
Kim, Jenny J.
Zheng, Lianqing
Rossi, John M.
Locke, Frederick L.
BLOOD, 2020, 135 (23) : 2106 - 2109
[3] Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.
Locke, Frederick Lundry
Ghobadi, Armin
Lekakis, Lazaros J.
Miklos, David Bernard
Jacobson, Caron A.
Jacobsen, Eric D.
Braunschweig, Ira
Oluwole, Olalekan O.
Siddiqi, Tanya
Lin, Yi
Reagan, Patrick Michael
Farooq, Umar
Deol, Abhinav
Bot, Adrian
Rossi, John M.
Jiang, Yizhou
Xue, Allen
Go, William Y.
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1
Locke, Frederick L.
Ghobadi, Armin
Jacobson, Caron A.
Jacobsen, Eric
Miklos, David B.
Lekakis, Lazaros J.
Braunschweig, Ira
Oluwole, Olalekan O.
Lin, Yi
Siddiqi, Tanya
Deol, Abhinav
Reagan, Patrick M.
Farooq, Umar
Bot, Adrian
Jiang, Yizhou
Rossi, John M.
Xue, Allen
Go, William Y.
Neelapu, Sattva S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S277 - S278
[5] Durability of Response in ZUMA-1, the Pivotal Phase 2 Study of Axicabtagene Ciloleucel in Patients With Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 16 - 18
[6] Outcomes of Patients Aged 65 Years in ZUMA-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma
Neelapu, Sattva S.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Deol, Abhinav
Miklos, David B.
Bartlett, Nancy L.
Braunschweig, Ira
Jiang, Yizhou
Kim, Jenny J.
Zheng, Lianging
Rossi, John M.
Locke, Frederick L.
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S19 - S20
[7] Retreatment of Patients With Refractory Large B Cell Lymphoma With Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
Locke, Frederick
Bartlett, Nancy
Jacobson, Caron
Oluwole, Olalekan
Munoz, Javier
Lekakis, Lazaros
Topp, Max
Avivi, Irit
Kim, Jenny
Chu, Rong
Zheng, Lianqing
Rossi, John
Bot, Adrian
Neelapu, Sattva
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S21 - S22
[8] Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.
Locke, Frederick Lundry
Ghobadi, Armin
Jacobson, Caron A.
Jacobsen, Eric D.
Miklos, David Bernard
Lekakis, Lazaros J.
Braunschweig, Ira
Oluwole, Olalekan O.
Lin, Yi
Siddiqi, Tanya
Deol, Abhinav
Reagan, Patrick Michael
Farooq, Umar
Bot, Adrian
Jiang, Yizhou
Rossi, John M.
Xue, Allen
Go, William Y.
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] RESULTS BY PRIOR LOT IN ZUMA-1, PIVOTAL STUDY PHASE 1/2 OF AXICABTAGEN CILOLEUCEL (AXI-CEL) IN PATIENTS WITH LARGE CELL LYMPHOMA B REFRACTORY
Locke, F. L.
Ghobadi, A.
Lekakis, L. J.
Miklos, D. B.
Jacobson, C. A.
Jacobsen, E.
Braunschweig, I
Oluwole, O. O.
Siddiqi, T.
Lin, Y.
Reagan, P. M.
Farooq, U.
Deol, A.
Bot, A.
Rossi, J. M.
Jiang, Y.
Xue, A.
Go, W. Y.
Neelapu, S. S.
HAEMATOLOGICA, 2018, 103 : 96 - 96
[10] Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL).
Neelapu, Sattva Swarup
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Deol, Abhinav
Miklos, David Bernard
Bartlett, Nancy L.
Braunschweig, Ira
Jiang, Yizhou
Kim, Jenny J.
Zheng, Lianqing
Rossi, John M.
Locke, Frederick Lundry
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →